title: Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study.
abstract: Six patients from the phase 3 trials of zoledronic acid in Paget's disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar absolute nadirs of serum alkaline phosphatase to those recorded after their first dose. No significant adverse events were reported. It is concluded that, while re-treatment of Paget's disease with zoledronic acid is rarely needed, it is safe and effective, with no evidence of treatment resistance based on this small cohort.
authors.affiliation: Faculty of Medical and Health Sciences, University of Auckland , Auckland, New Zealand.
authors.forename: Ian R
authors.initials: IR
authors.lastname: Reid
authors.affiliation: Department of Medicine, Laval University , Quebec City, Quebec, Canada.
authors.forename: Jacques P
authors.initials: JP
authors.lastname: Brown
authors.affiliation: Department of Medicine, University of Cape Town , Observatory, South Africa.
authors.forename: Naomi
authors.initials: N
authors.lastname: Levitt
authors.affiliation: Servicio de Reumatología, Hospital Universitario y Politécnico La Fe , Valencia, Spain.
authors.forename: José A
authors.initials: JA
authors.lastname: Román Ivorra
authors.affiliation: Servicio de Reumatología, Hospital Ramon Y Cajal , Madrid, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Bachiller-Corral
authors.affiliation: Department of Medicine, University of Cape Town , Observatory, South Africa.
authors.forename: Ian L
authors.initials: IL
authors.lastname: Ross
authors.affiliation: Novartis Pharmaceuticals Corporation , East Hanover, NJ, USA.
authors.forename: Guoqin
authors.initials: G
authors.lastname: Su
authors.affiliation: Novartis Pharmaceuticals Corporation , East Hanover, NJ, USA.
authors.forename: Oscar
authors.initials: O
authors.lastname: Antunez-Flores
authors.affiliation: Novartis Pharmaceuticals Corporation , East Hanover, NJ, USA.
authors.forename: R Paul
authors.initials: RP
authors.lastname: Aftring